Biocryst Pharmaceuticals (BCRX) Total Debt Growth (5y) (2016 - 2026)
Biocryst Pharmaceuticals (BCRX) Total Debt Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.76% |
| Dec 31, 2025 | -20.70% |
| Sep 30, 2025 | 38.19% |
| Mar 31, 2025 | 47.24% |
| Dec 31, 2024 | 107.57% |
| Sep 30, 2024 | 47.31% |
| Jun 30, 2024 | 47.05% |
| Mar 31, 2024 | 46.47% |
| Dec 31, 2023 | 61.28% |
| Sep 30, 2023 | 58.37% |
| Jun 30, 2023 | 71.09% |
| Mar 31, 2023 | 60.83% |
| Dec 31, 2022 | 58.42% |
| Sep 30, 2022 | 57.49% |
| Jun 30, 2022 | 44.43% |
| Mar 31, 2022 | 43.70% |
| Dec 31, 2021 | 67.26% |
| Sep 30, 2021 | 41.84% |
| Sep 30, 2020 | 8.94% |
| Mar 31, 2020 | 10.99% |